First-line treatment choices and patient profiles in advanced non-small cell lung cancer
Official title: DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First-line Treatment Patterns Observational Study (Prospective and Survey); Evaluation Patterns of Choice in First Line Treatment of Metastatic NSCLC
Run by AstraZeneca · NCT07109154 · Data updated 2026-11-12
This project will collect electronic medical record data from adults with advanced non‑small cell lung cancer starting first‑line treatment to see if real‑world care and biomarker use (like driver mutations and PD‑L1) match guideline recommendations.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | AstraZeneca Industry-sponsored |
| Locations | 7 sites (Recife and 6 other locations) |
| Status | Recruiting |
| Started | November 25, 2025 |
| Main results expected | April 30, 2027 |
| Study ends | April 30, 2027 |
| Registry record updated | May 13, 2026 |
| Trial ID | NCT07109154 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults over 18 with unresectable or metastatic non‑small cell lung cancer who start first‑line oncologic treatment at one of the participating centers between January 2025 and January 2026 and have data in electronic medical records.
✕Probably not a fit
Patients with localized disease suitable for local treatment, non‑epithelial histologies, small cell carcinoma, neuroendocrine tumors, those treated outside participating centers, or without electronic records are not eligible and will not benefit from inclusion.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, observational, multicenter cohort that will extract demographic and clinical data from electronic medical records for a convenience sample of about 200 patients across participating centers. Eligible patients are adults with advanced (unresectable or metastatic) non‑small cell lung cancer who begin first‑line systemic treatment between January 2025 and January 2026. Patients with localized disease amenable to local therapy, non‑epithelial histologies, small cell carcinoma, neuroendocrine tumors, or prior PACIFIC‑protocol treatment are excluded. The project also includes a physician survey to capture the factors that influence first‑line regimen selection.
Why it matters
Potential benefit: If successful, the study could reveal gaps in guideline‑concordant first‑line care and biomarker testing that inform improvements in treatment access and decision making.
How similar studies have gone: Similar real‑world analyses of NSCLC treatment patterns and biomarker use have been done and have repeatedly identified regional gaps in guideline adherence and testing, so the approach is established though findings vary by setting.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Advanced (unresectable or metastatic) non-small cell lung carcinoma * First-line oncological treatment in one of the participating centers between 2025 and 2026 (between January 2025 and January 2026) * \> 18 years old * Data available in electronic medical records. Exclusion Criteria: * Localized disease amenable to local treatment * Non-epithelial histology * Small cell carcinoma * Neuroendocrine tumor * Patients with unresectable NSCLC who underwent treatment with the PACIFIC protocol and are being followed up.
Where it's running
-
Research Site
Rio de Janeiro, Brazil Recruiting -
Research Site
Salvador, Brazil Recruiting -
Research Site
Recife, Brazil Active not recruiting -
Research Site
Rio de Janeiro, Brazil Not yet recruiting -
Research Site
Salvador, Brazil Not yet recruiting -
Research Site
São Paulo, Brazil Active not recruiting
Show 1 more location
-
Research Site
São Paulo, Brazil Not yet recruiting
Study contacts
- Principal investigator: Clarissa Baldotto — Instituto D'Or de Pesquisa e Ensino
- Study coordinator: AstraZeneca Clinical Study Information Center
- Email: information.center@astrazeneca.com
- Phone: 1-877-240-9479
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI-assisted longitudinal CT to guide indeterminate lung nodules
This trial tests whether giving doctors an AI report that tracks nodules over serial CT scans helps reduce unnecessary benign lung resections in patients with indeterminate nodules.
-
MRD-guided postoperative monitoring and adaptive treatment for resectable NSCLC
This study tests a personalized follow-up and treatment plan using ctDNA MRD testing and pathology to guide adjuvant therapy after surgery for stage IB-IIIA NSCLC treated with neoadjuvant immunotherapy.
-
Telerehabilitation exercise program after lung cancer surgery
A remote rehabilitation program with guided exercises is tested to help adults after lung cancer surgery recover better.
-
Impact of Exercise on Tumor Immunity in NSCLC Patients Receiving Neoadjuvant Chemo-Immunotherapy
A structured exercise program is being tested to see if it boosts immune cells in the tumor for patients with resectable NSCLC undergoing pre-surgery chemo-immunotherapy.
-
Low-Dose CT Lung Cancer Screening in Kuwait: Feasibility and Uptake
This pilot tests whether offering low-dose CT lung cancer screening to high-risk adults in Kuwait is workable and acceptable, with about 500 participants completing a baseline scan.
-
Nitride-based Raman biochip for lung cancer diagnosis and monitoring
A large observational study in Taiwan will test whether a blood-based nitride-based Raman biochip can help diagnose lung cancer and monitor patients over time.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.